Skip to content
Hair Pipeline
← Back to the pipeline

SYHX1901

An undisclosed CSPC candidate at phase 2 in androgenetic alopecia.

Phase 2OtherUndisclosed
Developed by
CSPC Pharmaceutical Group
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Indications
Androgenetic alopecia
Last public activity
June 2025
Record confidence
Low

Why it matters

CSPC is one of China's largest pharmaceutical groups, and a phase 2 from a company that size is a stronger signal than the same phase from a startup — it implies a development budget behind it. Nothing about the compound is disclosed.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT06562894 — Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT06562894Phase 2NOT YET RECRUITING

    Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

    CSPC Ouyi Pharmaceutical Co., Ltd. · n=156 · May 2025

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources